Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALMR
Alamar Biosciences
$30.57
+0.3%		$28.50
$18.84
▼
$38.54
$2.12BN/A314,561 shs206,972 shs
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$128.53
-1.6%		$106.51
$58.83
▼
$132.70
$719.77M0.97148,915 shs126,545 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$7.37
-0.1%		$6.73
$2.30
▼
$9.42
$1.91B0.62.47 million shs2.76 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$16.83
+0.6%		$14.38
$4.73
▼
$18.89
$1.76B2.312.70 million shs2.49 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALMR
Alamar Biosciences
+3.85%-10.53%+12.63%+41.88%+3,048,999,900.00%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
+4.13%+2.75%+25.11%+19.72%+103.47%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
+1.10%-17.08%+14.95%+47.90%+211.39%
Personalis, Inc. stock logo
PSNL
Personalis
-1.93%-2.05%+26.74%+38.26%+247.82%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALMR
Alamar Biosciences
$30.57
+0.3%		$28.50
$18.84
▼
$38.54
$2.12BN/A314,561 shs206,972 shs
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$128.53
-1.6%		$106.51
$58.83
▼
$132.70
$719.77M0.97148,915 shs126,545 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$7.37
-0.1%		$6.73
$2.30
▼
$9.42
$1.91B0.62.47 million shs2.76 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$16.83
+0.6%		$14.38
$4.73
▼
$18.89
$1.76B2.312.70 million shs2.49 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALMR
Alamar Biosciences
+3.85%-10.53%+12.63%+41.88%+3,048,999,900.00%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
+4.13%+2.75%+25.11%+19.72%+103.47%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
+1.10%-17.08%+14.95%+47.90%+211.39%
Personalis, Inc. stock logo
PSNL
Personalis
-1.93%-2.05%+26.74%+38.26%+247.82%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALMR
Alamar Biosciences
2.43
Hold$31.804.02% Upside
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
2.00
Hold$110.00-14.42% Downside
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.00
Hold$6.25-15.20% Downside
Personalis, Inc. stock logo
PSNL
Personalis
2.20
Hold$14.54-13.63% Downside

Current Analyst Ratings Breakdown

Latest MLAB, ALMR, MRVI, and PSNL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/24/2026
Personalis, Inc. stock logo
PSNL
Personalis
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$16.25
8/14/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$94.00 ➝ $110.00
8/11/2026
ALMR
Alamar Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D+)
8/11/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Hold (C-)
8/11/2026
ALMR
Alamar Biosciences
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$28.00 ➝ $32.00
8/11/2026
ALMR
Alamar Biosciences
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$32.00 ➝ $35.00
8/7/2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$5.50 ➝ $6.50
7/21/2026
Personalis, Inc. stock logo
PSNL
Personalis
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/20/2026
Personalis, Inc. stock logo
PSNL
Personalis
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$16.25
7/20/2026
Personalis, Inc. stock logo
PSNL
Personalis
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$11.00 ➝ $16.25
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALMR
Alamar Biosciences
$74.21M28.58N/AN/A$4.51 per share6.78
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$249.13M2.89$12.06 per share10.66$33.73 per share3.81
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$185.74M10.30$0.42 per share17.44$1.37 per share5.38
Personalis, Inc. stock logo
PSNL
Personalis
$69.65M25.30N/AN/A$2.25 per share7.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALMR
Alamar Biosciences
-$29.82M-$1.96N/AN/AN/AN/AN/AN/AN/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$6.71M$0.84153.01N/AN/A1.92%22.72%9.82%11/5/2026 (Estimated)
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$130.77M-$0.52N/AN/AN/A-37.07%-15.70%-8.17%11/5/2026 (Estimated)
Personalis, Inc. stock logo
PSNL
Personalis
-$81.27M-$1.09N/AN/AN/A-153.84%-46.47%-35.30%11/3/2026 (Estimated)

Latest MLAB, ALMR, MRVI, and PSNL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
ALMR
Alamar Biosciences
-$0.36-$0.22+$0.14-$0.22N/A$29.43 million
8/10/2026Q1 2027
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
N/A$2.68N/A$0.49N/A$60.14 million
8/6/2026Q2 2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.0435-$0.02+$0.0235-$0.08$48.67 million$51.44 million
8/4/2026Q2 2026
Personalis, Inc. stock logo
PSNL
Personalis
-$0.2633-$0.30-$0.0367-$0.30$16.69 million$22.36 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALMR
Alamar Biosciences
N/AN/AN/AN/AN/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$0.640.50%N/A76.19%N/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A

Latest MLAB, ALMR, MRVI, and PSNL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/6/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
quarterly$0.160.5%8/31/20268/31/20269/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALMR
Alamar Biosciences
0.03
11.85
10.23
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
0.73
1.79
1.32
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.49
4.05
2.98
Personalis, Inc. stock logo
PSNL
Personalis
N/A
5.28
5.08

Institutional Ownership

CompanyInstitutional Ownership
ALMR
Alamar Biosciences
N/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
90.60%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
50.25%
Personalis, Inc. stock logo
PSNL
Personalis
61.91%

Insider Ownership

CompanyInsider Ownership
ALMR
Alamar Biosciences
N/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
2.80%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.49%
Personalis, Inc. stock logo
PSNL
Personalis
4.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALMR
Alamar Biosciences
22269.39 millionN/AN/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
6805.60 million5.44 millionNot Optionable
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
610259.67 million253.21 millionOptionable
Personalis, Inc. stock logo
PSNL
Personalis
400104.72 million100.32 millionOptionable

Recent News About These Companies

Personalis, Inc. (PSNL) Stock Price, News, Quote & History - Yahoo Finance
September 2 at 7:58 AM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/PSNL/latest-news/
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Recommendation of “Hold” by Brokerages
September 2 at 4:00 AM  |  defenseworld.netD
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of "Hold" by Brokerages
September 2 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30997975
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Recommendation of "Hold" by Brokerages
September 2 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-personalis-inc-nasdaq-psnl-given-consensus-recommendation-of-hold-by-brokerages-2026-09-02/
66,188 Shares in Personalis, Inc. $PSNL Acquired by Deutsche Bank AG
September 1 at 3:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-66188-shares-in-personalis-inc-psnl-acquired-by-deutsche-bank-ag-2026-09-01/
7,082,491 Shares in Personalis, Inc. $PSNL Bought by BlackRock Inc.
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-7082491-shares-in-personalis-inc-psnl-bought-by-blackrock-inc-2026-08-30/
Personalis stock is up 250% in the past year. It needs to turn a profit next.
August 27, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/personalis-stock-is-up-250-in-the-past-year-it-needs-to-turn-a-profit-next/ar-AA2aZric
Personalis (NASDAQ:PSNL) Shares Gap Down on Analyst Downgrade
August 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30983263
Personalis (NASDAQ:PSNL) Rating Lowered to "Hold" at Craig Hallum
August 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30983071
Personalis falls amid a downgrade as a competitive bid appears unlikely
August 24, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/personalis-falls-amid-a-downgrade-as-a-competitive-bid-appears-unlikely/ar-AA2aQa07
Personalis (NASDAQ:PSNL) Shares Gap Down After Analyst Downgrade
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/personalis-nasdaqpsnl-shares-gap-down-after-analyst-downgrade-2026-08-24/
Personalis (NASDAQ:PSNL) Rating Lowered to Hold at Craig Hallum
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/personalis-nasdaqpsnl-rating-lowered-to-hold-at-craig-hallum-2026-08-24/
Contrasting Personalis (NASDAQ:PSNL) and Telesis Bio (NASDAQ:TBIO)
August 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30977560
Green Alpha Advisors LLC Takes $904,000 Position in Personalis, Inc. $PSNL
August 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-green-alpha-advisors-llc-takes-904000-position-in-personalis-inc-psnl-2026-08-22/
Personalis (NASDAQ:PSNL) Trading Up 8.7% - What's Next?
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/personalis-nasdaqpsnl-trading-up-87-whats-next-2026-08-21/
Renaissance Technologies LLC Decreases Position in Personalis, Inc. $PSNL
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-decreases-position-in-personalis-inc-psnl-2026-08-21/
Personalis secures new Million Veteran Program task order
August 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/personalis-secures-new-million-veteran-program-task-order?utm_source=marketbeat.com&utm_medium=referral
Personalis (NASDAQ:PSNL) Hits New 1-Year High - Here's Why
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/personalis-nasdaqpsnl-hits-new-1-year-high-heres-why-2026-08-20/
Moderna’s cancer breakthrough just made Tempus AI’s $1.5 billion bet look brilliant
August 19, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/moderna-s-cancer-breakthrough-just-made-tempus-ai-s-15-billion-bet-look-brilliant/ar-AA2auWKN
Personalis (NASDAQ:PSNL) Shares Gap Up - Here's Why
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/personalis-nasdaqpsnl-shares-gap-up-heres-why-2026-08-19/
Merck & Co. Inc. Purchases New Position in Personalis, Inc. $PSNL
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-purchases-new-position-in-personalis-inc-psnl-2026-08-18/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alamar Biosciences NASDAQ:ALMR

$30.57 +0.08 (+0.26%)
As of 04:00 PM Eastern

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. We commercially launched our proprietary instrument, the ARGO High Throughput (“HT”) System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries and a cumulative installed base of over 100 instruments with an average annual pull-through greater than $400,000 per instrument for the year ended December 31, 2025. The robust performance of our platform is further evidenced in over 100 scientific publications since our commercial launch. Our customers include top global research and academic institutions, biopharmaceutical companies, contract research organizations and service labs. All ten of the top ten biopharma companies by 2024 revenue are customers of Alamar. We are also developing a second proprietary instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027. We have established multiple multi-million dollar collaborations with renowned research foundations to help support the development of our ARGO HT/DX instrument and the discovery of biomarkers in neurodegenerative disease. Proteins are essential for all life functions and the fundamental molecules behind healthy cellular operations and the causal mechanisms of disease, as illustrated by the fact that a large majority of effective drugs have proteins as targets. Proteomic analysis has great potential to identify “biomarkers” of health, to characterize disturbances in disease, to discover new drug targets, to assess risks and to measure the impact of interventions such as drugs and lifestyle changes. However, the complexity of disease and biology requires analysis of multiple proteins and pathways at once. As a result of this complexity, much of the human proteome has remained unmeasurable or unquantifiable by other proteomic technologies, and true Precision Proteomics has not been possible. Our proprietary and patented NULISA technology addresses these critical limitations, and we believe it is currently the only platform that enables Precision Proteomics. The chemistry underpinning our technology employs a unique sequential purification of immunocomplexes to suppress background noise and enable the detection of low-abundance protein targets in biofluids across large and diverse populations. Our platform is a fully integrated and fully automated proteomic analysis solution and provides scientists with an end-to-end solution to precisely and consistently measure from one to over one hundred low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research, and ultimately, diagnostics. Scientists value our platform because it offers an accessible, easy-to-use and reliable ultra-high sensitivity and multiplexed biomarker analysis of large cohorts of samples. Our current instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is currently available for research use only (“RUO”) applications. It was built to execute our NULISA chemistry in a simple and reproducible workflow for broad biomarker profiling, validation and potential translation into future clinical use. The ARGO HT System facilitates the seamless analysis of large cohorts and clinical research with minimal handling, rapid turnaround times and high data quality. Our initial assay menu focuses on neurology and immunology. We develop a significant portion of our assay panels in close partnership with our customers, who are experts in identifying important protein biomarkers in their respective fields. Our flagship multiplex assay, the CNS Disease Panel 120, provides broad coverage of neurodegeneration pathways. Additionally, our single-plex BD-pTau217 assay can distinctly measure brain-derived-pTau217, which is present in low abundance in blood and is critical for research involving biomarkers for early diagnosis of Alzheimer’s disease. Our assay enables BD-pTau217 quantitation using a small blood sample, offering a noninvasive, economical and convenient alternative to cerebrospinal fluid sample tests or PET scans. We also develop kits for customers to create their own assays, enabling our technology to meet the needs of customers operating in their disease areas of interest. The flexibility of our platform is designed to enable researchers to seamlessly transition from high-plex discovery panels to the development of low-plex diagnostics assays. As a result, our strategy is to continue driving adoption in the targeted discovery and translational markets and subsequently establish a foundation for clinical diagnostics through internal innovation and external collaborations. Ultimately, our platform is designed to support the entire customer journey from discovery to diagnostics, unlocking the full value of precision medicine and early disease detection. We were founded in May 2018 as a Delaware corporation. Our principal executive offices are located in Fremont, California.

Mesa Laboratories stock logo

Mesa Laboratories NASDAQ:MLAB

$128.53 -2.12 (-1.62%)
As of 04:00 PM Eastern

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Maravai LifeSciences stock logo

Maravai LifeSciences NASDAQ:MRVI

$7.37 -0.01 (-0.14%)
As of 04:00 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Personalis stock logo

Personalis NASDAQ:PSNL

$16.83 +0.10 (+0.60%)
As of 04:00 PM Eastern

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas